Characterising pathogenic variant type in BRCA1, and future screening for deletions overlapping SULT1A1, may produce variables to be incorporated with other modifying factors to develop a more comprehensive model of breast cancer risk. This evidence concerns the gene SULT1A1 and breast cancer.